Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

Abstract Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in pati...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-07-01
coleção:	BMC Nephrology
Assuntos:	Coagulation, thrombotic disorders and therapies, Cancer and thrombosis Eculizumab Gemcitabine-induced thrombotic microangiopathy
Acesso em linha:	https://doi.org/10.1186/s12882-021-02470-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!